(Total Views: 640)
Posted On: 09/03/2020 10:05:34 PM
Post# of 153964
My apologies, it was Scott Kelly who spoke about biopsies, or rather, diagnostics that might prevent biopsies. At the 23:30:00 mark.
It wasn’t Daniel Adams from CreatV BioTech.
Scott Kelly -
“As we move forward we will continue to look for biomarkers to show the effectiveness of Leronlimab. We will continue to look at cutting edge diagnostics like Cancer Associated Macrophage-like Cells, or CAMLs, and Circulating Tumor Cell, or CTCs. This will all happen with our collaboration with CreatV MicroTech. We believe CAMLs and CTCs have the potential to provide a minimally invasive alternative to tissue biopsies, to determine cancer therapy and monitor treatment response and recurrence.”
It wasn’t Daniel Adams from CreatV BioTech.
Scott Kelly -
“As we move forward we will continue to look for biomarkers to show the effectiveness of Leronlimab. We will continue to look at cutting edge diagnostics like Cancer Associated Macrophage-like Cells, or CAMLs, and Circulating Tumor Cell, or CTCs. This will all happen with our collaboration with CreatV MicroTech. We believe CAMLs and CTCs have the potential to provide a minimally invasive alternative to tissue biopsies, to determine cancer therapy and monitor treatment response and recurrence.”
(2)
(0)
